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Poster Session-II 101that, overall, these 2 regimens allows similar reduced TRM and
high one-year OS for hematological malignancies and could be se-
lected for further phase III comparison with myeloablative regi-
men. Further details of sub-group analysis (disease status; acute
leukemia, NHL and MM) will be presented in order to assess
this conclusion in specific situations with a median study follow-up
of 44 [6 – 78] months.276
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Due to the shift of allogeneic stem cell transplantation (SCT) to
poor risk cases in chronic myeloid leukemia (CML), therapy of
relapse after SCT is highly relevant. In contrast to Imatinib
(IM), where application in stem cell recipients was investigated
in many studies, studies on 2nd generation tyrosine kinase inhib-
itors (TKIs) in the post-transplantat period are limited. We
performed evaluation of 25 stem cell recipients with CML and
13 with Phil positive ALL (Phi1ALL). 9 of those pts received
2nd generation TKIs in the post-transplant period (CML blast
phase; BP: n 5 6; CML accelerated phase; AP: n 5 2; Phi1ALL;
n 5 1). There were 5 males and 4 females (median age 54 years).
Before allo-SCT, 7 were in hematological remission, 8 pts were
MRD positive. 3 pts had Imatinib resistance conferring mutations
(T315I, Y253H, L387F). All pts received unrelated SCT after
myeloablative/reduced conditioning. Indications for the post-
transplant application of dasatinib were as follows: Phi1ALL: mo-
lecular relapse: n 5 1; CML: relapse of BP: n 5 2, extramedullary
CML relapse with skeletal/cutaneous or central nervous manifes-
tations: n 5 4, refractory extramedullary manifestation: n 5 1,
persisting MRD: n 5 1. The median interval between SCT and
dasatinib was 7 months (3–19). Before start of dasatinib after
SCT, 4 cases had been refractory to imatinib. Starting dose of da-
satinib was 2  70 mg or 2  50 mg. Dose escalation was possible
in 3 pts; reduction was necessary in 1 pt. In 1 pt dasatinib was in-
terrupted due to gastrointestinal intolerance/thrombocytopenia.
Median treatment duration was 9 months (range 1–17). 3 cases
showed response to therapy: 1 pt is in stable major mol. remission,
2 other patients are in partial remission of extramedullary relapse.
1 pt suffers from meningeosis leukemica and receives intrathecal
cytarabine. Due to refractoriness, the ALL pt was transferred to
nilotinib. 4 pts (44%) died after 6, 7, 9, and 33 months from
SCT due to progression. Median overall survival after start of da-
satinib was 10 months. In conclusion, although the limited sample
has to be considered, it seems that dasatinib can be administered
with acceptable tolerance in the post-transplant period and is
able to stabilize the situation in single cases of extramedullary or
hematological relapse after SCT even in advanced disease and in
a poor-risk situation. Future prospective studies should further
evaluate the best application schedules of 2nd generation TKIs
in the post-transplant period.277
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Umbilical cord blood (UCB) is a viable source of hematopoietic
stem cells (HSC) however, because of the risk of nonengraftment
with low total nucleated cell counts (TNC) per kg, double UCB
(DCB) transplants are used in larger patients (pts). We conducteda retrospective review of DCB transplants (n 5 30) from January
2004 through April 2008 compared to bone marrow (n 5 23,
30%) and peripheral blood (n 5 54, 70%) unrelated donor (UD)
transplants during the same time period. Median age was 21 yrs
(range 13–66) for DCB recipients and 45 yrs (range 0.4–67) for
UD pts. UD pts were HLA typed at A, B, C, DR, and DQ and
matched with donors at 9(10) (21%) and 10(10) (79%) loci [all
mismatches at class I alleles]. DCB recipients had HLA matches
of 6/6, 5/6/, 4/6 and 3/6 as follows: (cord 1/ cord 2): (0.0%/
6.7%), (20.0%/30.0%), (76.7%/63.3%), (3.3%/0.0%). The
median TNC/kg in DCB pts was 2.03  107 (range 7.9  106 –
9.3  108). Median day to ANC.500/ul for DCB and UD pts
was 23 days (range 6–66) and 15 days (range 7–52), and platelet
.20,000/ul was 52 days (range 7–130) and 19 days (range 9–63), re-
spectively. Incidences of acute GVHD $2 and chronic GVHD in
the UD and DCB pts were 61.0% and 51% vs. 53.3% and 45%, re-
spectively. Median follow-up was 143 days (range 12–847) for the
DCB group and 242 days (range 34–1506) for the UD pts. Esti-
mated overall survival (OS) at 1 year was 61% (95% CI: 48% to
71%) for UD pts vs. 55% (95% CI: 34% to 72%) in DCB pts
(p 5 NS). Estimated transplant related mortality (TRM) at 100
days for UD pt was 6.5% (95% CI: 2.8% to 14.9%) and 16.7%
(95% CI: 7.3% to 35.5%) (p5 0.09) in DCB pts. All facility trans-
plant related costs were reviewed from the transplant center thru
the first year post transplant, excluding pretransplant workup and
care not received at the transplant center. The total median costs
for DCB transplants were significantly more than the UD costs
at D30, D100 and 1yr post transplant by differences of $42,067,
$50,806, and $52,297, respectively (p\0.05 for each time interval).
The median length of stay for initial hospitalization at start of
preparative regimen was 22 days (2–144) in the UD pts and 29
days (6–103) in the DCB pts, and 60% of total median costs oc-
curred by D30 in the DCB group compared to 52% in the UD
group. In conclusion, DCB provides a viable option for HSC
with comparable clinical outcomes to UD transplants, however
DCB transplants are more expensive primarily because of inpatient
costs in the first 30 days.278
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In 2005, the United States Congress passed the Stem Cell
Therapeutic and Research Act. A central component of this leg-
islation was the development of the National Cord Blood Inven-
tory (NCBI). A competitive bidding process was instituted and to
date three cohorts of banks have been funded with the charge to
collect and store 150,000 new cord blood units. A goal in the de-
velopment of this new inventory is to increase the number of cord
blood units from underrepresented racial and ethnic groups. The
St. Louis Cord Blood Bank (SLCBB) began participating in this
program in September of 2007. The focus for our bank in achiev-
ing the goal of diversification was to establish strategies for re-
cruiting African American donors. Historically, this ethnic
group has not widely participated in cord blood donation in the
St. Louis area. A pilot study was instituted by the SLCBB at
SSM St. Mary’s Health Center in October of 2007. This hospital
was chosen due to its diverse patient population. We hypothe-
sized that the insertion of a dedicated staff nurse into this facility,
to educate and communicate directly with potential donors,
would result in a significant increase in donations from African
Americans. The results from this study are dramatic. A total of
448 cord blood units were collected during the study period (Oc-
tober 1, 2007 – September 30, 2008) as compared to 54 cord
blood units during the previous 12 month period (p 5
\0.0001). This equates to a 730% increase in African American
donations. This pilot study demonstrated that the SLCBB initia-
tive was successful not only in increasing the donation rate among
African Americans, but also an awareness of the life-saving bene-
fits of cord blood. While donations have increased at a significant
